

NeuroSearch A/S  
Pederstrupvej 93  
DK - 2750 Ballerup  
Denmark  
Telephone: +45 4460 8000  
Telefax: +45 4460 8080  
ns@neurosearch.dk  
www.neurosearch.com  
CVR No: DK-12 54 61 06

## Announcement

### NeuroSearch A/S – Share purchase programme – Status update

In announcement no. 15-09 of 7 May 2009, NeuroSearch announced the launch of a share purchase programme under which the company will buy own shares for an amount of up to DKK 50 million during 2009.

The programme is structured according to European Commission Regulation No 2273/2003 of 22 December 2003, also referred to as the “Safe Harbour” rules, for the purchase of own shares.

In the past week, since the issue of status announcement no. 29-09 of 27 July 2009, no transactions have been made under NeuroSearch’s share purchase programme:

NeuroSearch holds a total of 191,123 treasury shares of DKK 20 nominal value each, corresponding to 1.17% of the total number of 16,274,030 issued shares in NeuroSearch A/S.

An amount of DKK 29,569,200 remains to be used under the share purchase programme. Based on the closing price for NeuroSearch shares on NASDAQ OMX Copenhagen on Friday 27 July 2009, this corresponds to a maximum of 256.010 additional NeuroSearch shares to be bought under the programme.

Flemming Pedersen  
CEO

### Contact persons

Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118

### About NeuroSearch

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq OMX Copenhagen. The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Company and GlaxoSmithKline (GSK), and a license collaboration with Abbott. The drug pipeline comprises seven clinical (Phase I-III) development programmes: Pridopidine (ACR16) for Huntington’s disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 for the treatment of dyskinesias in Parkinson’s disease (Phase II ready), ACR343 for schizophrenia (Phase II ready), ABT-560 for the treatment of cognitive dysfunctions (Phase I) in partnership with Abbott and NSD-788 for anxiety (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.

